Overview

Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Status:
Completed

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

The primary purpose of the study is to determine, whether the addition of 5-azacytidine to standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results (event free survival).

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital Muenster

Collaborators:

Amgen
Celgene Corporation

Treatments:

Azacitidine
Cytarabine
Daunorubicin